DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth

Rhea-AI Summary

DSS (NYSE American: DSS) has announced the sale of its Celios® air purification technology to Impact BioMedical (NYSE American: IBO) in an all-equity transaction valued at $1.15 million. The strategic divestiture is part of DSS's portfolio optimization strategy to focus on core growth areas.

Celios® features a patented three-stage filtration system capable of removing ultrafine particles as small as 10 nanometers, enhancing indoor air quality and reducing airborne health risks. According to CEO Jason Grady, this transaction allows DSS to streamline its holdings and concentrate on business segments with stronger long-term synergies.

Positive

• Strategic divestiture generates $1.15M in equity value
• Portfolio optimization to focus on core growth areas
• Streamlined operations for better resource allocation

Negative

• Loss of innovative technology asset from portfolio
• All-equity transaction structure (no immediate cash proceeds)

Insights

Financial Analyst

DSS's divestiture of Celios® to Impact BioMedical for $1.15 million in an all-equity transaction represents a significant strategic realignment for the micro-cap company. With DSS's market capitalization at just $7.62 million, this transaction accounts for approximately 15% of its market value, making it a material development for investors.

The all-equity structure is particularly noteworthy as it suggests DSS sees potential upside in Impact BioMedical's future performance rather than prioritizing immediate cash infusion. This transaction effectively transforms DSS's direct ownership of air purification technology into a financial investment in Impact BioMedical, potentially reducing operational complexity while maintaining exposure to the asset's upside.

For DSS shareholders, this move signals management's commitment to portfolio rationalization after years of maintaining diverse business lines. By divesting non-core assets, DSS can redirect resources toward its primary growth initiatives while potentially improving operating margins and capital efficiency. The company's micro-cap status makes such focus particularly crucial, as smaller companies often lack the scale to effectively compete across multiple unrelated segments.

The timing of this divestiture suggests management may be anticipating either market challenges in the air purification sector or identifying more promising opportunities elsewhere that demand capital reallocation. This transaction likely represents just one component of a broader strategic pivot, and investors should watch for additional portfolio adjustments as management continues streamlining operations.

While the immediate financial impact appears modest, the long-term strategic implications could be significant if this represents the beginning of a more disciplined approach to capital allocation and business focus at DSS.

ROCHESTER, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company focused on innovation-driven business models, today announced the sale of its Celios® air purification asset to Impact BioMedical Inc. (NYSE American: IBO) in a strategic, all-equity transaction valued at approximately $1.15 million. This divestiture aligns with DSS’ ongoing strategy to optimize its portfolio and concentrate on core growth areas.

Celios® is a cutting-edge air purification technology featuring a patented three-stage filtration system capable of removing ultrafine particles as small as ten (10) nanometers, helping to improve indoor air quality and mitigate airborne health risks. The sale of this asset allows DSS to focus on other high-impact investments across its diversified business segments.

“The sale of Celios® to Impact BioMedical represents another step in our strategic efforts to streamline our holdings and focus on our core business objectives,” said Jason Grady, CEO of DSS, Inc. “Impact BioMedical is well-positioned to leverage Celios’® innovative air purification technology, and we believe this transition will maximize the platform’s potential while allowing DSS to continue to focus into areas with stronger long-term synergies.”

This transaction strengthens DSS’ commitment to advancing its strategic vision by concentrating on key business verticals that drive long-term shareholder value.

About DSS, Inc.:

DSS, Inc. (NYSE American: DSS) is a multinational company operating businesses across multiple high-growth sectors. DSS focuses on creating, acquiring, and investing in innovative companies that drive sustainable value for its shareholders.

About Celios®:

Celios® is an advanced air purification technology company committed to improving indoor air quality through patented filtration solutions. Designed for efficiency and portability, Celios® systems provide industry-leading air purification that meets the highest standards of cleanliness and safety.

Safe Harbor Statement:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve risks and uncertainties that may cause actual results to differ materially from those projected. DSS, Inc. disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contact:
DSS Inc. Investor Relations
Email: IR@dssworld.com
Phone: +1 (585) 565-2422

FAQ

How much did DSS sell Celios® air purification technology for?

DSS sold Celios® to Impact BioMedical in an all-equity transaction valued at approximately $1.15 million.

What are the key features of the Celios® air purification system sold by DSS?

Celios® features a patented three-stage filtration system that can remove ultrafine particles as small as 10 nanometers, improving indoor air quality.

Why did DSS sell its Celios® technology to Impact BioMedical?

DSS sold Celios® as part of its strategic effort to streamline holdings and focus on core business objectives with stronger long-term synergies.

What type of transaction was the DSS Celios® sale to Impact BioMedical?

The sale was structured as an all-equity transaction, meaning the payment was made in stock rather than cash.